Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-06-30
2000-09-26
Davis, Zinna Northington
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514375, 514393, 548218, 548 151, 5483021, A61K 31425, A61K 3142, C07D51322, C07D49800, C07D48700
Patent
active
061243310
ABSTRACT:
This invention is directed to tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
REFERENCES:
Khazi et. al., Synthesis and Biological Activity of some 2-amino/arylamino-4H-(1)benzothiopyrano [4,3-d] thiazoles, Indian Journal of Heterocyclic Chemistry, pp. 243-248, 1995.
Marzabadi Mohammad R.
Noble Stewart A.
Wong Wai C.
Davis Zinna Northington
Robinson Binta
Synaptic Pharmaceutical Corporation
White John P.
LandOfFree
Selective NPY (Y5) antagonists (tricyclics) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective NPY (Y5) antagonists (tricyclics), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective NPY (Y5) antagonists (tricyclics) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100647